Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827296 | 0.89 | PAOX (0.41) | AAK1ALDH1A1LMNAKMT2AFAAH | |
| SCHEMBL18827297 | 0.87 | PAOX (0.48) | ALDH1A1LMNAKMT2AFAAH | |
| SCHEMBL25063765 | 0.82 | EPHX2 (0.45) | ALDH1A1LMNAKMT2ARAB9APOLB | |
| SCHEMBL18104670 | 0.82 | BCHE (0.44) | ALDH1A1LMNAKMT2AFAAHHSD17B10 | |
| SCHEMBL9911437 | 0.82 | RAB9A (0.50) | ALDH1A1LMNAKMT2ARAB9AMAPT | |
| SCHEMBL24808265 | 0.80 | ALDH1A1 (0.39) | AAK1ALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL22525933 | 0.80 | KDM4E (0.41) | ALDH1A1LMNAKMT2ARAB9AFAAH | |
| SCHEMBL25884918 | 0.80 | KMT2A (0.50) | ALDH1A1LMNAKMT2AFAAHHSD17B10 | |
| SCHEMBL23059841 | 0.78 | ALDH1A1 (0.39) | AAK1ALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL9911444 | 0.78 | ECE1 (0.47) | ALDH1A1LMNAKMT2ARAB9AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | AAK1 4300/4885ALDH1A1 2197/4885LMNA 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.